Sirnaomics Plans $300 Million Hong Kong IPO for RNAi Portfolio

Sirnaomics Plans $300 Million Hong Kong IPO for RNAi Portfolio

Sirnaomics, a Maryland-Suzhou RNAi therapeutics company, filed to raise $300 million in a Hong Kong IPO. Sirnaomics has two siRNA therapeutics that target TGF-β1 and COX-2 for either local or systemic administration to treat cancers and fibrotic diseases. Both are in Phase II trials in the US and China. The initial filing did not announce a financial goal for the offering, but data in the prospectus implied a $300 million target. Sirnaomics completed a $105 million Series E round earlier this month after raising the same amount in a Series D last year. For further information, see ChinaBio Today (http://www.chinabiotoday.com/articles/siraonomics-300-million-hk-ipo) ...
Read More
AXA IM Alts raises €1.9 billion for European Life Sciences investments

AXA IM Alts raises €1.9 billion for European Life Sciences investments

AXA IM Alts, a global leader in alternative investments with c. €162 billion of assets under management, has raised €1.9 billion of equity to accelerate investments into the Life Sciences sector. The capital was raised over the last seven months, with commitments to a significantly oversubscribed fund raise from a range of clients from North America, Asia and Europe. AXA IM Alts’ investments into the life science sector on behalf of clients are managed by its Real Assets platform, the leading real estate portfolio and asset manager in Europe. Already well established in the U.S., Life Sciences is an emerging ...
Read More
Kernal Biologics Enters Development Phase Reaching Critical Milestones for its First mRNA-Based Cancer-Therapeutic Product

Kernal Biologics Enters Development Phase Reaching Critical Milestones for its First mRNA-Based Cancer-Therapeutic Product

Kernal Biologics, Inc. (Kernal Bio) — an early-development-stage mRNA-technology company developing cancer therapeutics designed to improve patients’ survival rate and quality of life — is on a fast track to transition out of proof-of-concept phase to product development. According to Co-founder and Chief Executive Officer Yusuf Erkul, M.D., the company has recruited a powerhouse team, which has enabled Kernal Bio to meet key scientific milestones. Kernal Bio’s mRNA technology combines two proprietary mRNA encryption designs, increasing the potential to improve patient outcomes resulting from an unprecedented level of onco-selectivity the company expects to achieve compared to existing synthetic mRNA technologies ...
Read More
Junshi Forms $16 Million mRNA JV with Hangzhou's Immorna

Junshi Forms $16 Million mRNA JV with Hangzhou’s Immorna

Shanghai Junshi Bio formed a mRNA Joint Venture with Hangzhou's Immorna to develop new drugs for cancer, plus infectious and rare diseases. Initially, the JV will have a value of $16 million with Junshi contributing half of that in cash and Immora adding in its mRNA IP for the other half. Junshi, a company best known for developing the first domestically developed PD-1 drug approved in China, said it would invest up to $123 million in the JV. Immorna focuses on process development and optimization of mRNA and delivery vehicles along with R&D of novel nucleic acid drugs. For further information, see ...
Read More
ShapeTX Earns $112 Million Series B to Support Gene Therapy Development Projects

ShapeTX Earns $112 Million Series B to Support Gene Therapy Development Projects

Seattle biotechnology firm Shape Therapeutics has announced that it generated $112 million from a recent Series B financing round it co-led with Decheng Capital and Breton Capital. The amount is intended to support the company's growing portfolio of RNA technologies and accelerate efforts to develop various treatment approaches in the gene therapy field. Shape has developed a suite of platforms that broadly enable RNA targeting, editing, and replacement for patients who have been diagnosed with genetic disorders and have a high unmet need. The news comes on the heels of its discovery of next-generation adeno associated viruses (AAVs), which are specific to ...
Read More
Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology

Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced on July 13th that it has entered into an exclusive licensing agreement with Bicycle Therapeutics plc (NASDAQ: BCYC) to increase the delivery capabilities of Ionis' advanced LIgand Conjugated Antisense (LICA) medicines. The agreement provides Ionis exclusive access to Bicycle's proprietary macrocyclic peptides, referred to as Bicycles, to design LICAs that target transferrin receptor 1 for use with oligonucleotides. This LICA strategy has demonstrated both the improved delivery of antisense medicines to muscle tissue, including cardiac muscle, as well as the potential to cross the blood brain barrier. Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, Bicycles, for diseases that ...
Read More
Valneva’s chikungunya virus vaccine granted breakthrough designation

Valneva’s chikungunya virus vaccine granted breakthrough designation

French speciality vaccine company Valneva has announced that its single-shot chikungunya vaccine candidate has received a breakthrough therapy designation from the US Food and Drug Administration (FDA). The chikungunya vaccine – VLA1553 – has also previously been awarded an FDA fast track designation and a European Medicines Agency (EMA) PRIME designation, in December 2018 and October 2020 respectively. Chikungunya is a mosquito-borne viral disease caused by the chikungunya virus. Although the mortality with chikungunya virus is low, morbidity is high, with clinical symptoms including acute onset of fever, debilitating joint and muscle pain, headache, rash, nausea and chronic arthralgia. For ...
Read More

Sirnaomics Plans $300 Million Hong Kong IPO for RNAi Portfolio

Sirnaomics Plans $300 Million Hong Kong IPO for RNAi Portfolio

Sirnaomics, a Maryland-Suzhou RNAi therapeutics company, filed to raise $300 million in a Hong Kong IPO. Sirnaomics has two siRNA therapeutics that target TGF-β1 and COX-2 for either local or systemic administration to treat cancers and fibrotic diseases. Both are in Phase II trials in the US and China. The initial filing did not announce a financial goal for the offering, but data in the prospectus implied a $300 million target. Sirnaomics completed a $105 million Series E round earlier this month after raising the same amount in a Series D last year. For further information, see ChinaBio Today (http://www.chinabiotoday.com/articles/siraonomics-300-million-hk-ipo) ...
Read More
AXA IM Alts raises €1.9 billion for European Life Sciences investments

AXA IM Alts raises €1.9 billion for European Life Sciences investments

AXA IM Alts, a global leader in alternative investments with c. €162 billion of assets under management, has raised €1.9 billion of equity to accelerate investments into the Life Sciences sector. The capital was raised over the last seven months, with commitments to a significantly oversubscribed fund raise from a range of clients from North America, Asia and Europe. AXA IM Alts’ investments into the life science sector on behalf of clients are managed by its Real Assets platform, the leading real estate portfolio and asset manager in Europe. Already well established in the U.S., Life Sciences is an emerging ...
Read More
Kernal Biologics Enters Development Phase Reaching Critical Milestones for its First mRNA-Based Cancer-Therapeutic Product

Kernal Biologics Enters Development Phase Reaching Critical Milestones for its First mRNA-Based Cancer-Therapeutic Product

Kernal Biologics, Inc. (Kernal Bio) — an early-development-stage mRNA-technology company developing cancer therapeutics designed to improve patients’ survival rate and quality of life — is on a fast track to transition out of proof-of-concept phase to product development. According to Co-founder and Chief Executive Officer Yusuf Erkul, M.D., the company has recruited a powerhouse team, which has enabled Kernal Bio to meet key scientific milestones. Kernal Bio’s mRNA technology combines two proprietary mRNA encryption designs, increasing the potential to improve patient outcomes resulting from an unprecedented level of onco-selectivity the company expects to achieve compared to existing synthetic mRNA technologies ...
Read More
Junshi Forms $16 Million mRNA JV with Hangzhou's Immorna

Junshi Forms $16 Million mRNA JV with Hangzhou’s Immorna

Shanghai Junshi Bio formed a mRNA Joint Venture with Hangzhou's Immorna to develop new drugs for cancer, plus infectious and rare diseases. Initially, the JV will have a value of $16 million with Junshi contributing half of that in cash and Immora adding in its mRNA IP for the other half. Junshi, a company best known for developing the first domestically developed PD-1 drug approved in China, said it would invest up to $123 million in the JV. Immorna focuses on process development and optimization of mRNA and delivery vehicles along with R&D of novel nucleic acid drugs. For further information, see ...
Read More
ShapeTX Earns $112 Million Series B to Support Gene Therapy Development Projects

ShapeTX Earns $112 Million Series B to Support Gene Therapy Development Projects

Seattle biotechnology firm Shape Therapeutics has announced that it generated $112 million from a recent Series B financing round it co-led with Decheng Capital and Breton Capital. The amount is intended to support the company's growing portfolio of RNA technologies and accelerate efforts to develop various treatment approaches in the gene therapy field. Shape has developed a suite of platforms that broadly enable RNA targeting, editing, and replacement for patients who have been diagnosed with genetic disorders and have a high unmet need. The news comes on the heels of its discovery of next-generation adeno associated viruses (AAVs), which are specific to ...
Read More
Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology

Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced on July 13th that it has entered into an exclusive licensing agreement with Bicycle Therapeutics plc (NASDAQ: BCYC) to increase the delivery capabilities of Ionis' advanced LIgand Conjugated Antisense (LICA) medicines. The agreement provides Ionis exclusive access to Bicycle's proprietary macrocyclic peptides, referred to as Bicycles, to design LICAs that target transferrin receptor 1 for use with oligonucleotides. This LICA strategy has demonstrated both the improved delivery of antisense medicines to muscle tissue, including cardiac muscle, as well as the potential to cross the blood brain barrier. Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, Bicycles, for diseases that ...
Read More
Valneva’s chikungunya virus vaccine granted breakthrough designation

Valneva’s chikungunya virus vaccine granted breakthrough designation

French speciality vaccine company Valneva has announced that its single-shot chikungunya vaccine candidate has received a breakthrough therapy designation from the US Food and Drug Administration (FDA). The chikungunya vaccine – VLA1553 – has also previously been awarded an FDA fast track designation and a European Medicines Agency (EMA) PRIME designation, in December 2018 and October 2020 respectively. Chikungunya is a mosquito-borne viral disease caused by the chikungunya virus. Although the mortality with chikungunya virus is low, morbidity is high, with clinical symptoms including acute onset of fever, debilitating joint and muscle pain, headache, rash, nausea and chronic arthralgia. For ...
Read More
Sirnaomics Plans $300 Million Hong Kong IPO for RNAi Portfolio

Sirnaomics Plans $300 Million Hong Kong IPO for RNAi Portfolio

Sirnaomics, a Maryland-Suzhou RNAi therapeutics company, filed to raise $300 million in a Hong Kong IPO. Sirnaomics has two siRNA therapeutics that target TGF-β1 and COX-2 for either local or systemic administration to treat cancers and fibrotic diseases. Both are in Phase II trials in the US and China. The initial filing did not announce a financial goal for the offering, but data in the prospectus implied a $300 million target. Sirnaomics completed a $105 million Series E round earlier this month after raising the same amount in a Series D last year. For further information, see ChinaBio Today (http://www.chinabiotoday.com/articles/siraonomics-300-million-hk-ipo) ...
Read More
AXA IM Alts raises €1.9 billion for European Life Sciences investments

AXA IM Alts raises €1.9 billion for European Life Sciences investments

AXA IM Alts, a global leader in alternative investments with c. €162 billion of assets under management, has raised €1.9 billion of equity to accelerate investments into the Life Sciences sector. The capital was raised over the last seven months, with commitments to a significantly oversubscribed fund raise from a range of clients from North America, Asia and Europe. AXA IM Alts’ investments into the life science sector on behalf of clients are managed by its Real Assets platform, the leading real estate portfolio and asset manager in Europe. Already well established in the U.S., Life Sciences is an emerging ...
Read More
Kernal Biologics Enters Development Phase Reaching Critical Milestones for its First mRNA-Based Cancer-Therapeutic Product

Kernal Biologics Enters Development Phase Reaching Critical Milestones for its First mRNA-Based Cancer-Therapeutic Product

Kernal Biologics, Inc. (Kernal Bio) — an early-development-stage mRNA-technology company developing cancer therapeutics designed to improve patients’ survival rate and quality of life — is on a fast track to transition out of proof-of-concept phase to product development. According to Co-founder and Chief Executive Officer Yusuf Erkul, M.D., the company has recruited a powerhouse team, which has enabled Kernal Bio to meet key scientific milestones. Kernal Bio’s mRNA technology combines two proprietary mRNA encryption designs, increasing the potential to improve patient outcomes resulting from an unprecedented level of onco-selectivity the company expects to achieve compared to existing synthetic mRNA technologies ...
Read More
Junshi Forms $16 Million mRNA JV with Hangzhou's Immorna

Junshi Forms $16 Million mRNA JV with Hangzhou’s Immorna

Shanghai Junshi Bio formed a mRNA Joint Venture with Hangzhou's Immorna to develop new drugs for cancer, plus infectious and rare diseases. Initially, the JV will have a value of $16 million with Junshi contributing half of that in cash and Immora adding in its mRNA IP for the other half. Junshi, a company best known for developing the first domestically developed PD-1 drug approved in China, said it would invest up to $123 million in the JV. Immorna focuses on process development and optimization of mRNA and delivery vehicles along with R&D of novel nucleic acid drugs. For further information, see ...
Read More
ShapeTX Earns $112 Million Series B to Support Gene Therapy Development Projects

ShapeTX Earns $112 Million Series B to Support Gene Therapy Development Projects

Seattle biotechnology firm Shape Therapeutics has announced that it generated $112 million from a recent Series B financing round it co-led with Decheng Capital and Breton Capital. The amount is intended to support the company's growing portfolio of RNA technologies and accelerate efforts to develop various treatment approaches in the gene therapy field. Shape has developed a suite of platforms that broadly enable RNA targeting, editing, and replacement for patients who have been diagnosed with genetic disorders and have a high unmet need. The news comes on the heels of its discovery of next-generation adeno associated viruses (AAVs), which are specific to ...
Read More
Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology

Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced on July 13th that it has entered into an exclusive licensing agreement with Bicycle Therapeutics plc (NASDAQ: BCYC) to increase the delivery capabilities of Ionis' advanced LIgand Conjugated Antisense (LICA) medicines. The agreement provides Ionis exclusive access to Bicycle's proprietary macrocyclic peptides, referred to as Bicycles, to design LICAs that target transferrin receptor 1 for use with oligonucleotides. This LICA strategy has demonstrated both the improved delivery of antisense medicines to muscle tissue, including cardiac muscle, as well as the potential to cross the blood brain barrier. Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, Bicycles, for diseases that ...
Read More
Valneva’s chikungunya virus vaccine granted breakthrough designation

Valneva’s chikungunya virus vaccine granted breakthrough designation

French speciality vaccine company Valneva has announced that its single-shot chikungunya vaccine candidate has received a breakthrough therapy designation from the US Food and Drug Administration (FDA). The chikungunya vaccine – VLA1553 – has also previously been awarded an FDA fast track designation and a European Medicines Agency (EMA) PRIME designation, in December 2018 and October 2020 respectively. Chikungunya is a mosquito-borne viral disease caused by the chikungunya virus. Although the mortality with chikungunya virus is low, morbidity is high, with clinical symptoms including acute onset of fever, debilitating joint and muscle pain, headache, rash, nausea and chronic arthralgia. For ...
Read More